The University of Debrecen, situated in Hungary's Debrecen city, is the country's oldest continuously functioning institution of higher education, dating back to 1538. The university offers an established English language program for international students, particularly in the field of medicine, which pioneered English education in 1986. Currently, nearly 5000 international students are enrolled at the university. The institution has a distinguished record, with five former students having won technical Academy Awards (Oscars) until 2014.

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Urogenital Diseases

Diagnostic radiopharmaceuticals

Radiolabeled antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	2
Radiolabeled antibody	2

Top 5 Target	Count

MUC1(Mucin-1)	1
VEGF-A(Vascular endothelial growth factor A)	1

Drugs associated with University of Debrecen

52Mn-DOTAGA-Bevacizumab

Target

VEGF-A

Mechanism

VEGF-A modulators

Active Org.

University of Debrecen

Originator Org.

University of Debrecen

Active Indication

Uterine Cervical Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

[111In]In-DOTA-PR81

Target

MUC1

Mechanism

MUC1 modulators

Active Org.

University of Debrecen

Originator Org.

University of Debrecen

Active Indication

Breast Cancer

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with University of Debrecen

NCT05709184 / RecruitingNot Applicable

Lyophilized Fecal Microbiome Transfer for Primary Clostridioides Difficile Infection (DONATE Study): a Multicenter Randomized Controlled Trial

The goal of this clinical trial is to test whether lyophilized fecal microbime transfer - a dried extract of bacteria from the stool of healthy donors - is better than antibiotic therapy only for treating primary clostridioides difficile infection (CDI) in adult participants.
The main question it aims to answer is whether lyophilized fecal microbiome transfer lowers the number of episodes of CDI compared to antibiotic therapy.
Participants will be assigned to one of two groups:
In the intervention group participants will be given vancomycin by mouth for five days followed by 5 days of capsules of lyophilized fecal microbiome to swallow, up until day 10.
In the control group participants will be given vancomycin by mouth for ten days.
All participants will be asked to arrive for two follow-up visits and to fill out questionnaires. In addition, all participants will be asked to give stool samples before antibiotic therapy and on the two follow-up visits.
Researchers will compare the intervention group and the control group to see if there is a difference in symptoms degree after ten days and in recurrence of the infection after two months. They will also compare side effects, the total use of antibiotics and the change in the composition of bacteria in the stool, namely the presence of bacteria that are resistant to many drugs.

Start Date15 Nov 2023

Sponsor / Collaborator

Rambam Health Care Campus

[+6]

NCT06313814 / Enrolling by invitationNot ApplicableIIT

The Effect of Ginger on Functional Dyspepsia Symptoms and Body Fat Content Among Patients With Functional Dyspepsia

The goal of this clinical trial is to assess ginger's effect on patients with functional dyspepsia.
The main question[s] it aims to answer are:
1. Does ginger intake improve functional dyspepsia symptoms?
2. Does ginger intake decrease the body fat content among patients with functional dyspepsia? Dyspepsia patients will be asked to take 540 mg of ginger capsule twice a day. Researchers will assess if there is an improvement in the symptoms of the disease and the fat content. [ to see if gingers effect.

Start Date01 Jun 2023

Sponsor / Collaborator

University of Debrecen

NCT05802771 / Not yet recruitingNot ApplicableIIT

Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice: the LANTERN Study

The goal of this multi-centric observational clinical trial is to to develop accurate predictive models for lung cancer patients, through the creation of Digital Human Avatars using various omics-based variables and integrating well-established clinical factors with "big data" and advanced imaging features
The main goals of LANTERN project are:
To develop prevention models for early lung cancer diagnosis;
To set up personalized predictive models for individual-specific treatments;
Lung cancer patients will be prospectively enrolled and main omics data (including radiomics and genomics) will be collected, reflecting the main omics domains associated with the lung cancer diagnosis and decision making pathway.
An exploratory analysis across all collected datasets will select a pool of potential biomarkers to create a multiple distinct multivariate models, trained though advanced machine learning (ML) and AI techniques sub-divided into specific areas of interest. Finally, the developed predictive models will be validated in order to test their robustness, transferability and generalizability, leading to the development of the Digital Human Avatar.

Start Date01 Jun 2023

Sponsor / Collaborator

Dresden University of Technology

[+2]

100 Clinical Results associated with University of Debrecen

0 Patents (Medical) associated with University of Debrecen

3,742

Literatures (Medical) associated with University of Debrecen

30 Jun 2023·Biomass and Bioenergy

Phosphorus fertilization rate and dynamics in early development of three giant reed (Arundo donax L.) ecotypes

Author: Elhawat, Nevien ; Csajbok, Jozsef ; Kovacs, Szilvia ; Veres, Szilvia ; Fari, Miklos G. ; Domokos-Szabolcsy, Eva ; Alshaal, Tarek

Recently, biomass crops attracted considerable attention as a possible alternative to fossil fuels; nevertheless, the interest in its agronomic practices such as irrigation and fertilization is still unclear. This study aims at determining the appropriate phosphorus (P) fertilization management in the early development stage of giant reed (Arundo donax L.). The uptake, transportation, and fertilization use efficiency of P were reported in three ecotypes of giant reed, i.e., STM (Hungary), BL (the USA), and ESP (Spain). Somatic embryo-derived plantlets were developed under glasshouse environment in clean sand (quartz) augmented with 0, 25, 50, 100, and 150 mg P kg^-1, added as monosodium phosphate. P-treated plants possessed a fibrous root system characterized by many lateral roots, while control plants (received no P) had a root system distinguished with long axial roots with very few lateral branches. Phosphorus uptake significantly varied according to plant ecotype, plant parts, and applied P concentration Giant reed ecotypes showed different responses to uptake and accumulation of P, where P contents in the STM, ESP and BL ecotypes were 392, 413, and 445 μg g^-1, resp. The accumulation of P in different plant parts was as follows: leaf blade > culm > root. The treatment of 50 mg P kg^-1 displayed the highest P content in all plant parts. The BL and STM ecotypes showed the same translocation factor (TF) of 4.96, while the ESP ecotype exhibited a lower TF of (4.03). The treatment of 50 mg P kg^-1 revealed the highest TF (5.94). The BL ecotype showed P use efficiency (PUE) of 7.08 compared with 6.49 and 5.85 for the ESP and STM ecotypes, resp. The 50 mg P kg^-1 exhibited the highest PUE (13.37). The BL ecotype displayed the highest CO₂ assimilation rate (12.46 μmol photons m^-2 s^-1). Also, the rate of CO₂ assimilation increased upon increasing the rate of the applied P. Our results reveal that the appropriate P fertilization rate of the ESP, STM, and BL ecotypes is 25, 25, and 50 mg P kg^-1, resp.

15 Mar 2023·Applied Surface Science

Selective and reversible surface complexation of aqueous palladium(II) by polycarboxylate (pyromellitic acid) functionalized hybrid aerogel sorbent

Author: Herman, Petra ; Moldovan, Krisztian ; Paul, Geo ; Marchese, Leonardo ; Balogh, Zoltan ; Len, Adel ; Dudas, Zoltan ; Fabian, Istvan ; Kalmar, Jozsef

The recovery of palladium compounds from aqueous solutions containing other metal salts is a challenging task of environmental technol. One solution is the development of selective sorbents by the appropriate design of surface functionality. For this purpose, a mesoporous, polycarboxylate (pyromellitic acid monoamide) functionalized silica-gelatin aerogel was prepared by the sol-gel method and supercritical drying. It is characterized using low voltage SEM (LV-SEM), N₂-sorption porosimetry, small angle neutron scattering (SANS), IR spectroscopy (FT-IR), solid-state NMR spectroscopy (ssNMR) and XPS. Its aqueous phase Zeta potential was investigated as a function of pH. The aerogel has excellent selectivity for binding Pd(II) around pH = 2.0 in the simultaneous presence of Pt(II), Pt(IV) and six other metal ions with a very high sorption capacity of 369 mg g^-1 at pH = 2.3. The quant. recovery of Pd(II) and the regeneration of the sorbent is possible using 5 mM methionine. The mechanism of binding is the reversible surface complexation of Pd(II) via the O-atoms of the adjacent carboxylate groups of the aerogel, as shown by XPS. This high stability coordination mode accounts for the excellent selectivity of the sorbent, and prevents the reduction of Pd(II).

15 Feb 2023·Applied Surface Science

Functionalizing aerogels with tetraazamacrocyclic copper(II) complexes: Nanoenzymes with superoxide dismutase activity

Author: Lihi, Norbert ; Balogh, Zoltan ; Dioszegi, Robert ; Forgacs, Attila ; Moldovan, Krisztian ; May, Nora V. ; Herman, Petra ; Fabian, Istvan ; Kalmar, Jozsef

The copper(II) complexes of 1,4,7,10-tetraazacyclododecane (cyclen) and 1,4,8,11- tetraazacyclotetradecane (cyclam) were covalently immobilized in mesoporous silica aerogels by the sol-gel method using functionalized silica precursors. The modified macrocyclic precursors are characterized by mass spectrometry (MS) and solution phase NMR (NMR) spectroscopy. The supercritically dried aerogels are characterized using low voltage SEM (LV-SEM), N₂-sorption porosimetry, IR spectroscopy (FT-IR), ESR spectroscopy (EPR) and contrast variation small angle neutron scattering (SANS). The suspended aerogel particles act as nanoenzymes, because they have significant SOD activities, dramatically higher than the corresponding dissolved Cu(II) complexes. The most important factors responsible for the altered reactivities due to the covalent immobilization of the complexes were elucidated based on the compiled results of the characterization methods. These are: i) the formation of new chem. environments and Cu(II) coordination modes; ii) the effective separation of the active Cu(II) centers in the aerogels; and iii) the confinement effect operative in the nanoporous network. As a perspective, the present functionalized aerogel microparticles can be developed into passive targeting antioxidant pharmaceutical agents administered locally or s.c.

News (Medical) associated with University of Debrecen

29 Sep 2022

·www.prnewswire.com

Lenire®, the treatment device shown to reduce tinnitus symptoms in 95% of patients, is now available in Hungary

More than 1 million Hungarians could experience tinnitus Tinnitus Klinika's 3 clinics will provide Lenire throughout Hungary Availability in Hungary follows publication of second large-scale clinical trial results, showing greater improvement in tinnitus symptoms BUDAPEST, Hungary, Sept. 29, 2022 /PRNewswire/ -- Irish medical device company, Neuromod Devices Ltd., which specialises in the treatment of tinnitus, has reached an agreement with Tinnitus Klinika kft, a provider of specialist tinnitus care, to make its Lenire device available in Hungary. Continue Reading Tamás Nagy, CEO & Owner of Tinnitus Klinika Tinnitus patient using Lenire Lenire is a bimodal neuromodulation device which has shown in analysis of real-world patients and multiple large-scale clinical trials to reduce the severity of tinnitus symptoms. Tinnitus, commonly known as "ringing in the ears", is a complex neurological condition resulting in the perception of sound without an external source. Landmark research into the prevalence of tinnitus in Europe was published in renowned scientific journal, The Lancet, in late 2021. It found that prevalence of any tinnitus was 14.7%i, which could mean that 1.4 million Hungarians experience the condition. Through this distribution agreement, Tinnitus Klinika's specialist team has exclusive licence from Neuromod to provide Lenire throughout Hungary to suitable patients for the treatment of their tinnitus. "I'm delighted to work with Tinnitus Klinika to make Lenire available to people living with tinnitus in Hungary. Tinnitus is globally recognised as a significant healthcare challenge and many people living with the condition have unmet clinical needs. Tinnitus specialists like Tinnitus Klinika deeply understand the needs of tinnitus patients and we're proud to be able to support them in improving therapeutic outcomes for their patients," explains Dr Ross O'Neill, Founder and CEO of Neuromod Devices. In the last 12 months Neuromod has expanded availability of Lenire in Europe, launching it in Denmark, Norway, Spain, Switzerland, and the UK. Earlier in 2022 the results of an independent real-world analysis were published in the peer-reviewed scientific journal, Brain Stimulation, demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients. The study found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms, as measured by THIii, following six to 12 weeks of treatment using Lenireiii. The device has also been used in large-scale clinical trials with over 500 patients. In June, the results of Lenire's second large-scale clinical trial were published in the highly regarded scientific journal, Nature – Scientific Reports. They showed a significant further breakthrough for improving tinnitus symptoms severity with Lenireiv. By changing the stimuli patients received halfway through their treatment plan, a clinically significant greater average improvement in tinnitus symptom severity was demonstratediv. 95% of treatment-compliant participants reported an improvement in their tinnitus symptoms, as measured by THIii,iv. 91% of treatment-compliant participants reported an improvement which sustained at least up to 12 months after treatment had endediv. Tinnitus Klinika's team have been providing specialist care for people living with tinnitus since it was founded in 2008 by Tamás Nagy, who holds a degree in Audiology from Oxford-Brookes University. The organisation operates 3 clinics in Hungary at Czeizel Institute in Budapest, Hallomás Center in Veszprém, and at Debrecen University in partnership with the University's Medical school. Tinnitus Klinika offers a suite of therapeutic interventions for people with tinnitus, which now includes Lenire, and has facilitated research of these interventions in their clinical practices under the guidance of the organisation's Advisory Board. "Tinnitus Klinika's partnership with Neuromod is a significant step forward for our tinnitus patients. I'm delighted to be able to provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world as part our suite of services for people living with the condition. I'm looking forward to working closely with Neuromod's team to achieve the best possible patient outcomes in our clinics ," explains Tamás Nagy, CEO at Tinnitus Klinika. Lenire is a bimodal neuromodulation device which combines mild electrical pulses to the tongue with sound stimulation to drive neuroplasticity in the brain which reduces the symptoms of tinnitus. It has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional and is currently available throughout Europe. The device consists of Bluetooth® headphones which play customised sounds to activate the auditory nerve, a proprietary intra-oral device which provides mild electrical stimulation to the surface of the tongue, known as a Tonguetip®, and a controller which controls the duration and intensity of treatment with the device. The device's sound and electrical stimuli can be calibrated to suit a patient's tinnitus after an initial assessment of their condition which includes an audiological exam. The supervising healthcare professional demonstrates how to use the device and provides the patient with instructions for use. Subsequently, patients use Lenire for 60 minutes per day typically for at least 10 weeks. Follow-up visits with the healthcare professional occur during treatment to monitor patients' progress. At the end of the prescribed treatment plan, the healthcare professional advises the patient about their continued use of Lenire. For more information please contact: Neil Doyle Global Director of Marketing, Neuromod Devices [email protected] About Neuromod Devices Ltd Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The lead application of Neuromod's technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. Neuromod's tinnitus treatment device, Lenire, is currently available throughout Europe. For more information visit . About Tinnitus Klinika kft Tinnitus Klinika kft, established in 2008, is a provider of specialist tinnitus care operating 3 clinics throughout Hungary at Czeizel Institute in Budapest, Hallomás Center in Veszprém, and at Debrecen University. Tinnitus Klinika provides a range of treatment interventions for people living with tinnitus. About Lenire Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe. Further details about Lenire including a list of providers can be found at . References (i) R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021), (ii) THI or Tinnitus Handicap Inventory is a clinical standard for measuring the impact of tinnitus on someone's day-to-day life. Measured on a scale of 100, the higher the score, the greater the impact of tinnitus. Reducing a person's THI score should correspond to improved quality of life by reducing how their tinnitus is affecting them. (iii) Buechner A, Lesinski-Schiedat A, Becker P, Lenarz T, Real-world clinical experience with bimodal neuromodulation for the treatment of tinnitus - A case series, Brain Stimulation (2022), doi: . (iv) Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, (2022) Photo: Photo: SOURCE Neuromod Devices Ltd

Collaborate

100 Deals associated with University of Debrecen

100 Translational Medicine associated with University of Debrecen

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 04 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

52Mn-DOTAGA-Bevacizumab ( VEGF-A )	Uterine Cervical Cancer More	Preclinical
[111In]In-DOTA-PR81 ( MUC1 )	Breast Cancer More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis